- Home
- CRDL vs BTMD Comparison
CRDL vs BTMD Comparison
Compare CRDL & BTMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDL
- BTMD
- Stock Information
- Founded
- CRDL 2017
- BTMD 2012
- Country
- CRDL Canada
- BTMD United States
- Employees
- CRDL N/A
- BTMD N/A
- Industry
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- BTMD Medicinal Chemicals and Botanical Products
- Sector
- CRDL Health Care
- BTMD Health Care
- Exchange
- CRDL Nasdaq
- BTMD Nasdaq
- Market Cap
- CRDL 90.4M
- BTMD 90.0M
- IPO Year
- CRDL N/A
- BTMD N/A
- Fundamental
- Price
- CRDL $1.22
- BTMD $2.90
- Analyst Decision
- CRDL Strong Buy
- BTMD Buy
- Analyst Count
- CRDL 2
- BTMD 2
- Target Price
- CRDL $9.00
- BTMD $6.00
- AVG Volume (30 Days)
- CRDL 859.1K
- BTMD 104.9K
- Earning Date
- CRDL 11-13-2025
- BTMD 11-05-2025
- Dividend Yield
- CRDL N/A
- BTMD N/A
- EPS Growth
- CRDL N/A
- BTMD 642.53
- EPS
- CRDL N/A
- BTMD 0.88
- Revenue
- CRDL N/A
- BTMD $199,073,000.00
- Revenue This Year
- CRDL N/A
- BTMD N/A
- Revenue Next Year
- CRDL N/A
- BTMD $4.85
- P/E Ratio
- CRDL N/A
- BTMD $3.30
- Revenue Growth
- CRDL N/A
- BTMD 6.32
- 52 Week Low
- CRDL $0.77
- BTMD $2.71
- 52 Week High
- CRDL $2.24
- BTMD $6.98
- Technical
- Relative Strength Index (RSI)
- CRDL 63.48
- BTMD 44.38
- Support Level
- CRDL $1.01
- BTMD $2.80
- Resistance Level
- CRDL $1.38
- BTMD $3.26
- Average True Range (ATR)
- CRDL 0.08
- BTMD 0.14
- MACD
- CRDL 0.02
- BTMD 0.02
- Stochastic Oscillator
- CRDL 58.60
- BTMD 34.52
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
About BTMD Biote Corp.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.